Skip to main content
SpringerLink
Log in

Bevacizumab: increased risk of venous thromboembolism

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: the Journal of the American Medical Association 300: 2277-2285, No. 19, 19 Nov 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab: increased risk of venous thromboembolism. React. Wkly. 1230, 3 (2008). https://doi.org/10.2165/00128415-200812300-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812300-00006

Keywords

Search

Navigation